| Literature DB >> 26383221 |
Alireza Davoudi, Narges Najafi, Shahriar Alian, Atefe Tayebi, Fatemeh Ahangarkani1, Samaneh Rouhi, Amirhosein Heydari.
Abstract
BACKGROUND: Patients who undergo cardiac surgery appear to be at increased risk for the development of Nosocomial infections (NIs). The development of antibiotic-resistant infections has been associated with significantly greater hospital mortality rates compared to similar infections caused by antibiotic-sensitive pathogens.Entities:
Mesh:
Year: 2015 PMID: 26383221 PMCID: PMC4803946 DOI: 10.5539/gjhs.v8n2p288
Source DB: PubMed Journal: Glob J Health Sci ISSN: 1916-9736
Demographic feature and risk factors of infection
| Respiratory tract Infection No. (%) | SSI No. (%) | UTI No. (%) | Blood Infection No. (%) | Mediastinitis No. (%) | Endocarditis No. (%) | Total No. (%) | ||
|---|---|---|---|---|---|---|---|---|
| Gender | Female | 22(45.5) | 22(42.3) | 22(68.78) | 8(50) | 1(16.7) | 16(48.5) | 90(48.) |
| Male | 26(54.5) | 30(57.7) | 10(31.25) | 8(50) | 5(83.3) | 17(51.5) | 97(51.9) | |
| Age | Year | 63.75±13.81 | 65±9.2 | 68±12.68 | 67.7±16.25 | 57±4.18 | 55.96±18.12 | 63.45±14.14 |
| Average duration of hospitalization | Day | 7.1±2.2 | 6.2±1.7 | 7.1±5.23 | 6.93±1.65 | 8.5±3.67 | 8.15±6.2 | 7.32±3.42 |
| Risk factor | Diabetes | 15(34.1) | 26(50) | 8(25) | 9(56.3) | 6(100) | 11(33.3) | 83(44.4) |
| HTN | 24(54.5) | 29(55.8) | 19(59.37) | 10(62.5) | 4(66.7) | 8(24.2) | 94(50.3) | |
| Cardiovascular disease | 21(31.7) | 22(42.3) | 11(34.37) | 8(50) | 4(66.7) | 5(15.2) | 71(38) | |
| Urine catheter | 13(27.8) | 13(25) | 23(71.87) | 7(43.8) | 6(100) | 9(27.3) | 101(54) | |
| Central venous device | 0 | 0 | 0 | 0 | 3(50) | 2(6.06) | 5(2.67) | |
| Mechanical intubation | 41(93.2) | 12(23.1) | 13(40.62) | 5(31.3) | 6(100) | 8(24.2) | 85(45.5) | |
| Steroid therapy | 1(2.3) | 0 | 3(9.37) | 0 | 0 | 4(12.1) | 8(4.3) | |
| Lung diseases | 5(11.4) | 11(21.2) | 6(18.75) | 0 | 0 | 2(6.1) | 24(12.7) | |
| Liver Cirrhosis | 2(4.5) | 0 | 2(6.25) | 0 | 0 | 0 | 4(2.1) | |
| Renal failure | 6(13.6) | 1(1.9) | 5(15.62) | 3(18.8) | 0 | 2(6.1) | 17(9.1) | |
| Malignancy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Chemotherapy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Transplantation | 0 | 0 | 3(1.6) | 0 | 0 | 0 | 3(1.6) |
Clinical characteristics of infection
| Respiratory tract Infection No. (%) | SSI No. (%) | UTI No. (%) | Blood Infection No. (%) | Mediastinitis | Endocarditis | Total No. (%) | ||
|---|---|---|---|---|---|---|---|---|
| Symptoms | Fever | 35(79.5) | 13(25) | 24(75) | 15(93.8) | 4(66.7) | 5(15.2) | 96(51.3) |
| Dysuria | 0 | 0 | 16(8.6) | 0 | 0 | 0 | 16(8.6) | |
| Frequent urination | 0 | 0 | 16(8.6) | 0 | 0 | 0 | 16(8.6) | |
| Flank pain | 0 | 0 | 4(2.1) | 0 | 0 | 0 | 4(2.1) | |
| Suprapobic pain | 0 | 0 | 3(1.6) | 0 | 0 | 0 | 3(1.6) | |
| Nausea | 0 | 0 | 0 | 0 | 0 | 1(.3) | 1(.3) | |
| Vomiting | 0 | 0 | 0 | 0 | 0 | 1(.3) | 1(.3) | |
| Chest pain | 5(11.4) | 1(1.9) | 0 | 1(6.3) | 0 | 1(.3) | 8(4.3) | |
| Cough | 9(20.5) | 0 | 0 | 0 | 0 | 1(.3) | 10(5.3) | |
| Increase of sputum | 39(88.6) | 0 | 3(1.6) | 0 | 6(100) | 0 | 48(25.7) | |
| Dyspnea | 32(72.7) | 1(1.9) | 6(3.2) | 4(25) | 4(66.7) | 1(.3) | 48(25.7) | |
| Wound erythema | 0 | 40(76.92) | 0 | 0 | 4(66.7) | 0 | 44(23.4) | |
| Wound oozing | 0 | 39(75) | 1(3.12) | 0 | 4(66.7) | 0 | 44(23.4) | |
| Suture openings | 0 | 16(30) | 0 | 0 | 0 | 0 | 16(8.6) |
Causative agent of Nis
| Causative agent by site | No.(%) episodes of infection | ||||||
|---|---|---|---|---|---|---|---|
| NO | SSI NO (%) 52(27.8) | Respiratory Infection NO (%) 48(25.6) | UTI NO (%) 32(17.1) | Blood Infection NO (%) 16(8.55) | Mediastinitis NO (%) 6(3.2) | Endocarditis NO (%) 33(17.6) | Total (N=187) NO (%) |
| 2(3.84) | 8(16.66) | 2(6.25) | 0 | 0 | 0 | 12(13.79%) | |
| 1(1.92) | 3(6.25) | 1(3.12) | 0 | 1(16.6) | 1(3.03) | 7(8.04%) | |
| 7(13.46) | 6(12.5) | 16(50) | 0 | 0 | 0 | 29(33.33%) | |
| 3(5.76) | 2(4.16) | 3(9.37) | 0 | 0 | 0 | 8(9.19%) | |
| 3(5.76) | 0 | 3(9.37) | 1(6.25) | 0 | 0 | 7(8.04%) | |
| 14(26.92) | 5(10.41) | 0 | 6(37.5) | 3(18.75) | 5(9.09) | 33(37.93%) | |
| 1(1.92) | 0 | 1(3.12) | 0 | 0 | 0 | 2(2.29%) | |
| Enterococci | 0 | 0 | 0 | 0 | 0 | 1(3.03) | 1(1.14%) |
| Culture negative | 21(4.3) | 20(41.66) | 6(18.75) | 9(56.25) | 2(33.33) | 26(78.78) | 88(47.1%) |
Antibiotic resistance pattern of gram negative bacteria isolated from infection
| Antibiotics | S | I | R | S | I | R | S | I | R | S | I | R | S | I | R |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ceftriaxone | 0 | 10 (83.3) | 2 (16.6) | 0 | 0 | 7 (100) | 3 (10.3) | 24 (82.75) | 2 (6.89) | 4 (50) | 3 (37.5) | 1 (12.5) | 0 | 3 (37.5) | 4 (57.1) |
| Ceftazidime | 2 (16.6) | 4 (33.3) | 6 (50) | 0 | 0 | 7 (100) | 3 (10.3) | 18 (62.06) | 8 (27.5) | 0 | 3 (37.5) | 5 (62.5) | 1 (14.2) | 1 (14.2) | 5 (71.42) |
| Ciprofloxacin | 2 (16.6) | 8 (66.6) | 2 (16.6) | 0 | 0 | 7 (100) | 3 (10.3) | 24 (82.7) | 2 (6.89) | 3 (37.5) | 3 (37.5) | 2 (25) | 1 (14.2) | 2 (28.5) | 4 (57.1) |
| Gentamicin | 10 (83.3) | 0 | 2 (16.6) | 0 | 0 | 7 (100) | 25 (86.2) | 2 (6.89) | 2 (6.89) | 3 (37.5) | 2 (25) | 3 (37.5) | 3 (37.5) | 1 (14.2) | 3 (42.85) |
| Amikacin | 10 (83.3) | 2 (16.6) | 0 | 0 | 0 | 7 (100) | 27 (93.1) | 0 | 2 (6.89) | 3 (37.5) | 2 (25) | 3 (37.5) | 4 (57.1) | 0 | 3 (42.85) |
| Imipenem | 10 (83.3) | 0 | 2 (16.6) | 0 | 0 | 7 (100) | 23 (79.3) | 2 (6.89) | 4 (13.8) | 2 (25) | 1 (12.5) | 5 (62.5) | 3 (37.5) | 1 (14.2) | 3 (42.85) |
| Novobiocin | 0 | 10 (83.3) | 2 (16.6) | 0 | 0 | 7 (100) | 8 (27.58) | 19 (65.51) | 2 (6.89) | 1 (12.5) | 2 (25) | 5 (62.5) | 3 (42.85) | 2 (28.5) | 2 (28.5) |
Antibiotic resistance of gram positive bacteria isolated from infection
| S | I | R | S | I | R | |
|---|---|---|---|---|---|---|
| Ampicillin | 4(12.9) | 15(48.38) | 12(38.70) | 0 | 2(100) | 0 |
| Penicillin | 0 | 19(61.29) | 12(38.70) | 0 | 2(100) | 0 |
| Oxacillin | 2(6.45) | 3(9.67) | 26(83.87) | 0 | 0 | 2(100) |
| Vancomycin | 30(96.77) | 0 | 1(3.22) | 2(100) | 0 | 0 |
| Clindamycin | 0 | 19(61.29) | 12(38.70) | 2(100) | 0 | 0 |
| Co-trimoxazole | 0 | 19(61.29) | 12(38.70) | 0 | 0 | 2(100) |
| Norfloxacin | 7(22.58) | 12(38.70) | 19(61.29) | 2(100) | 0 | 0 |
| Cefalotin | 17 | 7(22.58) | 7(22.58) | 0 | 2(100) | 0 |